UPDATE: Wells Fargo Out on Apellis Pharmaceuticals (APLS), Says Equity Pricing in Too Much Risk
Tweet Send to a Friend
(Updated - September 6, 2022 10:29 AM EDT)
Wells Fargo analyst Chris M. Carey reiterated an Overweight rating and ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Wells Fargo analyst Chris M. Carey reiterated an Overweight rating and ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
